International Cardio Corporation

International Cardio is a private U.S. medical device company developing noninvasive high-intensity focused ultrasound solutions for vascular disease. Its lead technology, the HIFU Synthesizer, is designed to image, target, and ablate vulnerable or occlusive plaque in peripheral arteries as an alternative to surgery, stenting, or balloon angioplasty. The company appears to be focused primarily on peripheral artery disease and related atherosclerotic conditions, with additional stated exploration in hypertension and pain management. Publicly available sources indicate first-human use of its system was reported in 2019, and the company has described its device as pre-CE mark. International Cardio also appears to leverage licensed intellectual property and academic collaboration with the University of Minnesota.